MedTrace Logo

Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

NCT00184366 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2012-01-19

No results posted yet for this study

Summary

The main objectives of the project are:

* To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI)
* To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.

Conditions

Interventions

DRUG

efalizumab

efalizumab

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Morten Dalaker, univ lekt II · St Olavs hospital, NTNU, Norway

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-05-31
Completion
2008-07-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00184366 on ClinicalTrials.gov